Wednesday June 19, 2019

Gut Bacteria Has The Ability To Contribute to Diabetes

"Our findings show clearly how important the interaction between gut microbiota and diet is to understand our metabolism in health and disease," said Backhed

0
//
Diabetes
Representational image. Pixabay

Gut bacteria has the ability to affect how cells respond to insulin and can thus contribute to Type-2 diabetes, says a new study.

The study explored that the gut microbiota of people with treatment-naive Type-2 diabetes can be linked to a different metabolism of the amino acid histidine, which is mainly derived from the diet.

This in turn leads to the formation of imidazole propionate, a substance that impairs the cells’ ability to respond to insulin. Therefore, reducing the amount of bacterial-produced imidazole propionate could be a new way of treating patients with such disease.

“This substance does not cause all Type-2 diabetes, but our working hypothesis is that there are sub-populations of patients who might benefit from changing their diet or altering their gut microbiota to reduce the levels of imidazole propionate,” said Fredrik Backhed, Professor at the University of Gothenburg in Sweden.

Diabetes
Representational image. Pixabay

For the study, published in the journal Cell, the research team involved 649 participants.

They used fecal samples and found that the microbiota of people with Type-2 diabetes produced imidazole propionate when histidine was added. However, this mechanism was not found in the diabetes-free control subjects.

Also read- Nearly 40 Individual HPV Types Linked to HIV Infection

“Our findings show clearly how important the interaction between gut microbiota and diet is to understand our metabolism in health and disease,” said Backhed.

The result also shows that gut bacteria from different individuals can lead to the production of completely different substances that may have very specific effects in the body,” he noted. (IANS)

Next Story

Researchers Find Drug to Delay Type-1 Diabetes by Two Years

The effects of the drug were greatest in the first year after it was given, said the study published online in The New England Journal of Medicine

0
Diabetes
Representational image. Pixabay

In a first, researchers have found that a treatment affecting the immune system effectively slowed the progression to clinical Type-1 diabetes in high risk individuals by two years or more.

“The results have important implications for people, particularly youth, who have relatives with the disease, as these individuals may be at high risk and benefit from early screening and treatment,” said Lisa Spain, Project Scientist from US National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The study, involving treatment with an anti-CD3 monoclonal antibody (teplizumab), was conducted by Type 1 Diabetes TrialNet, an international collaboration aimed at discovering ways to delay or prevent Type-1 diabetes.

Participants were randomly assigned to either the treatment group, which received a 14-day course of teplizumab, or the control group, which received a placebo.

All participants received glucose tolerance tests regularly until the study was completed, or until they developed clinical Type-1 diabetes – whichever came first.

During the trial, 72 per cent of the people in the control group developed clinical diabetes, compared to only 43 per cent of the teplizumab group.

diabetes
“Although Type-1 and Type-2 diabetes in parents are well-established risk factors for diabetes, we show that gestational diabetes mellitus may be a risk indicator for diabetes in the mother’s children before age 22,” . Pixabay

The median time for people in the control group to develop clinical diabetes was just over 24 months, while those who developed clinical diabetes in the treatment group had a median time of 48 months before progressing to diagnosis.

“The difference in outcomes was striking. This discovery is the first evidence we’ve seen that clinical Type-1 diabetes can be delayed with early preventive treatment,” Spain added.

Type-1 diabetes develops when the immune system’s T cells mistakenly destroy the body’s own insulin-producing beta cells.

Also Read- Cutting Sodium Intake May Prevent 94 Million Premature Deaths From CVD

Insulin is needed to convert glucose into energy. Teplizumab targets T cells to lessen the destruction of beta cells.

The effects of the drug were greatest in the first year after it was given, said the study published online in The New England Journal of Medicine. (IANS)